Table 2.

Surface phenotype, T-cell proliferative responses to various β2GPI preparations, predicted β2GPI domain containing the epitope, and HLA class II restriction in 14 β2GPI-specific CD4+ T-cell clones

T-cell clonesSurface phenotypeAntigen-induced T-cell proliferative responsePredicted β2GPI domain containing epitopeHLA class II restriction*
Native β2GPIReduced β2GPIGP1GP2GP3
Patient O.M.         
 OM2 CD4+CD8 − − − HLA-DR 
 OM3 CD4+CD8 − − − I/II HLA-DP 
 OM7 CD4+CD8 − − − HLA-DR 
 OM8 CD4+CD8 − − − − HLA-DR 
Patient E.Y.         
 EY3 CD4+CD8 − − − HLA-DR 
 EY8 CD4+CD8 − − − HLA-DR 
 EY9 CD4+CD8 − − − HLA-DR 
 EY12 CD4+CD8 − − − HLA-DR 
Patient K.S.         
 KS3 CD4+CD8 − − − HLA-DR 
 KS4 CD4+CD8 − − − HLA-DR 
 KS5 CD4+CD8 − − − HLA-DR 
 KS7 CD4+CD8 − − IV HLA-DR 
 KS8 CD4+CD8 − − − HLA-DR 
 KS10 CD4+CD8 − − IV HLA-DR 
T-cell clonesSurface phenotypeAntigen-induced T-cell proliferative responsePredicted β2GPI domain containing epitopeHLA class II restriction*
Native β2GPIReduced β2GPIGP1GP2GP3
Patient O.M.         
 OM2 CD4+CD8 − − − HLA-DR 
 OM3 CD4+CD8 − − − I/II HLA-DP 
 OM7 CD4+CD8 − − − HLA-DR 
 OM8 CD4+CD8 − − − − HLA-DR 
Patient E.Y.         
 EY3 CD4+CD8 − − − HLA-DR 
 EY8 CD4+CD8 − − − HLA-DR 
 EY9 CD4+CD8 − − − HLA-DR 
 EY12 CD4+CD8 − − − HLA-DR 
Patient K.S.         
 KS3 CD4+CD8 − − − HLA-DR 
 KS4 CD4+CD8 − − − HLA-DR 
 KS5 CD4+CD8 − − − HLA-DR 
 KS7 CD4+CD8 − − IV HLA-DR 
 KS8 CD4+CD8 − − − HLA-DR 
 KS10 CD4+CD8 − − IV HLA-DR 
*

Determined based on blocking experiments using anti-HLA-DR, anti-HLA-DQ, and anti-HLA-DP mAbs.

Close Modal

or Create an Account

Close Modal
Close Modal